Clinical Trial: Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma: a Prospective, Randomized, Open-label, Phase 2 Study
Brief Summary: The primary endpoint is to compare the PFS (progress-free survival ) of etoposide plus carboplatin with paclitaxel combined with carboplatin as first-line treatment for advanced pulmonary large cell neuroendocrine carcinoma.
Detailed Summary:
The primary endpoint is to compare the PFS (progress-free survival ) of etoposide plus carboplatin with paclitaxel combined with carboplatin as first-line treatment for advanced pulmonary large cell neuroendocrine carcinoma.
In addition, gene spectrum detection and Mini-PDX are applied for validation of pharmacodynamic.
Results of clinical trials and pharmacodynamic test will be analyzed to provide evidence for the precise treatment for LCNEC.
Sponsor: Shanghai Chest Hospital
Current Primary Outcome: Progression-free survival [ Time Frame: 6 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Tumor response [ Time Frame: 2 months ]
Original Secondary Outcome: Same as current
Information By: Shanghai Chest Hospital
Dates:
Date Received: October 22, 2016
Date Started: December 2016
Date Completion: December 2018
Last Updated: October 22, 2016
Last Verified: October 2016